Navigation Links
ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
Date:6/18/2012

SAN DIEGO, June 18, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company has been invited to participate in and present at the BIO Business Forum at the 2012 BIO International Convention, which is being held June 18 – 21, 2012 in Boston, MA.  Brian M. Culley, Chief Executive Officer of ADVENTRX, will present on Tuesday, June 19th at 9:30 a.m. EDT in the Celtics Room (104C) at the Boston Convention & Exhibition Center.

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)

"We look forward to participating in the BIO Business Forum, which will allow us to reach a global audience representing over 60 countries and to take advantage of the significant one-on-one partnering and networking opportunities at the convention," stated Mr. Culley.  "We believe in ANX-188's potential as an effective treatment for patients with sickle cell disease and are pleased to have the opportunity to continue to share its story with industry leaders and potential partners, particularly on June 19th, which is designated by the United Nations as World Sickle Cell Awareness Day." 

About BIO
The Biotechnology Industry Organization (BIO) represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The BIO Business Forum® has grown over the past eleven years to become the industry's largest partnering event, hosting a record breaking 21,000+ partnering meetings in 2011. More information can be found at www.bio.org.

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on developing proprietary product candidates.  The Company's lead product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding partnering and networking opportunities at the BIO International Convention and ANX-188's potential as an effective treatment for patients with sickle cell disease. Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and those indicated from the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but not limited to: the potential for ADVENTRX to delay, reduce or discontinue current and/or planned development activities, partner its product candidates at inopportune times or pursue less expensive but higher-risk development paths if it is unable to raise sufficient additional capital as needed; ADVENTRX's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for delays in the commencement or completion of its planned clinical studies including as a result of difficulties or delays in completing manufacturing process development activities and manufacturing clinical trial material; the risk of suspension or termination of a clinical study including due to lack of adequate funding; the risk that planned clinical studies of ADVENTRX's product candidates, including ANX-188, are not successful and, even if they are successful, that the FDA could determine they are not sufficient to support an NDA for the product candidate; the risk that the FDA does not grant market approval of ADVENTRX's product candidates, including ANX-188, on a timely basis, or at all; ADVENTRX's reliance on third parties to assist in the conduct of important aspects of its product candidates' development programs, including the manufacture of clinical trial material, the conduct of clinical studies and regulatory submissions related to product approval, and that such third parties may fail to perform as expected; the risk that intellectual property protection ADVENTRX obtains with respect to its product candidates, including ANX-188, is insufficient to provide a competitive advantage; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
2. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
3. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
4. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
5. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Valeant Pharmaceuticals To Host Investor Day
8. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
9. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
10. Nouveau Life Pharmaceuticals (NOUV) to Begin Sales of Azul Instant™
11. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
(Date:9/5/2017)... 2017  Just 18 months after its February 2016 ... announce the appointment of three new senior people to ... Dominic Jones-Phillips and James Wright bring ... Tammy Wynne joins as ... writers. She has over ten years, experience in global ...
(Date:9/1/2017)... -- Bayer will present the latest research from across its growing ... 2017 Congress, September 8-12 in Madrid, Spain ... data on Bayer,s marketed portfolio and late-stage compounds as well ... "We value the opportunity to meet ... ESMO," said Carsten Brunn , Head of Pharmaceuticals, Americas ...
Breaking Medicine Technology:
(Date:9/25/2017)... Angeles, CA (PRWEB) , ... September 25, 2017 , ... ... of a full-time office in downtown Los Angeles, to service existing clients in the ... surrounding areas. , “We are seeing an ever-increasing amount of business demand west of ...
(Date:9/24/2017)... ... , ... Bhowanie Benimadhu’s new book “ Our Creative World: Our Created Life ... answers in both Eastern and Western religious traditions and spirituality such as Hinduism ... of humankind for the past thousands of years and still are,” Benimadhu says. “By ...
(Date:9/24/2017)... ... September 24, 2017 , ... The Tuscany Resort on Grace Bay in ... Provo's premier boutique resorts, is planning on re-opening the resort on October 1st. ... Irma and more recently Hurricane Maria, and the staff and landscaping crews were fast ...
(Date:9/24/2017)... ... ... “Star of Bethlehem Study”: is a thought-provoking essay focusing on the most ... Duane Engdahl, an investigator who had has a long and eventful career in science ... a thought-provoking essay an event so significant that it is referred to as the ...
(Date:9/23/2017)... ... 23, 2017 , ... “You Can't Win Them All”: the story of an ... and on the ice changed the lives of young athletes. “You Can't Win ... born and educated in Schreiber, a small town in Northern Ontario, Canada. He ...
Breaking Medicine News(10 mins):